Barzolvolimab
Brand and Other Names:
Barzolvolimab
Mechanism of Action:
Indications:
Route:
Dose:
Adverse Reactions:
Contraindication:
Warnings and Precautions:
Investigational (Phase 2 trials)
GOOGLE OVERVIEW
Barzolvolimab is a humanized monoclonal antibody being developed to treat mast cell-mediated inflammatory diseases, such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). It works by inhibiting the KIT receptor, which is crucial for mast cell function and survival. Clinical trials have shown barzolvolimab to be effective in reducing disease activity and improving quality of life in patients with CSU.
More details:
-
Mechanism of Action:Barzolvolimab targets the KIT receptor, a protein on mast cells, preventing it from activating and thus reducing mast cell activity.
-
Clinical Trials:
- CSU: Phase 2 trials demonstrated that barzolvolimab significantly reduced disease activity and improved quality of life in patients with CSU.
-
- CIndU: Phase 2 trials showed that barzolvolimab can lead to complete responses in a significant percentage of patients with CIndU.
-
Efficacy:
Barzolvolimab has shown the ability to rapidly and significantly reduce symptoms in patients with CSU and CIndU.
Safety:
Barzolvolimab has been shown to have a favorable safety profile, with most adverse events being mild and reversible.
Potential Applications:
Besides CSU and CIndU, barzolvolimab is also being investigated for other mast cell-mediated diseases like prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis.
See package insert for full prescribing information.